Source comparison
Comparison Table: AHK-Cu vs TB-500 Research Characteristics
The following table summarizes the key biochemical, pharmacological, and application-specific differences between AHK-Cu and TB-500 for research planning. Molecular Weight ~340 Da (copper-bound) ~4,963 Da AHK-Cu's smaller size enables transdermal delivery; TB-
This comparison does not assign a generated winner or score.
- The following table summarizes the key biochemical, pharmacological, and application-specific differences between AHK-Cu and TB-500 for research planning.
- Molecular Weight
- ~340 Da (copper-bound)
- ~4,963 Da
- AHK-Cu's smaller size enables transdermal delivery; TB-500 requires injection
- Primary Mechanism
- Copper-dependent lysyl oxidase activation; collagen/elastin cross-linking
- G-actin sequestration; cytoskeletal regulation and cell migration
- Distinct pathways. Matrix remodeling vs cellular motility
- Metal Cofactor Requirement
- Absolute (requires copper chelation for activity)
- None (functions independently)
- AHK-Cu efficacy depends on copper bioavailability
- Administration Routes
- Topical, subcutaneous, intramuscular
- Subcutaneous, intramuscular only
- Topical option gives AHK-Cu advantage in dermal models
- Half-Life (tissue/plasma)
- 12–18 hours
- 24–36 hours
- TB-500's longer half-life supports twice-weekly dosing protocols
- Primary Research Applications
- Dermal wound healing, collagen synthesis studies, scar reduction models
- Systemic tissue repair, angiogenesis, muscle regeneration, cardiac research
- Select based on endpoint. Matrix composition (AHK-Cu) or cell behavior (TB-500)
- Reconstitution Stability
- 30 days at 2–8°C
- 28 days at 2–8°C
- Similar storage requirements once reconstituted
- Transdermal Penetration
- High (achieves dermal layer penetration)
- Negligible (molecular weight too large)
- Only AHK-Cu suitable for non-invasive topical protocols